Related references
Note: Only part of the references are listed.
Article
Immunology
Wenfang He et al.
Summary: Sepsis, characterized by host immune imbalance and organ dysfunction caused by infection, remains a formidable challenge with limited therapeutic options and high mortality rates. Recent studies have highlighted the potential of targeting NLRP3 inflammasome as a therapeutic strategy for sepsis. Activation of the NLRP3 inflammasome complex has been shown to play a critical role in the development and progression of sepsis, while inhibition of its activation can ameliorate the inflammatory response, protect organ function, and improve patient outcomes and survival.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Review
Medicine, Research & Experimental
Rohan Chakraborty et al.
Summary: Traumatic brain injury (TBI) caused by head trauma has significant consequences in terms of disability and healthcare cost. Neuroinflammation, particularly through the NLRP3 inflammasome, plays a crucial role in TBI. Inhibitors of the NLRP3 inflammasome show potential in reducing neuroinflammation and improving cognitive and motor function in TBI. However, clinical trials are needed to evaluate the efficacy of these promising therapeutic candidates.
Review
Biochemistry & Molecular Biology
Jie Xu et al.
Summary: The NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome is activated in response to cellular disturbances caused by infection and sterile injury. It triggers the release of inflammatory molecules and induces cell death. Understanding the structure and activation of NLRP3 inflammasome is important for studying inflammatory diseases.
TRENDS IN BIOCHEMICAL SCIENCES
(2023)
Review
Immunology
Salona Roy et al.
Summary: The article provides a comprehensive understanding of the role of NLRP3 inflammasome in the pathophysiology of depression-like chronic diseases. The activation pathways of NLRP3 have emerged as the main target for therapeutic management of depression. The available drug inhibitors for NLRP3 in preclinical and clinical trials are discussed in detail.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Gengzhen Huang et al.
Summary: Chronic kidney disease (CKD) is a global health concern and public health priority. The NLRP3 inflammasome, a multiprotein complex, plays an important role in inducing renal inflammation and fibrosis. Inhibitors targeting the NLRP3 inflammasome show promise as potential treatments for CKD.
BIOCHEMISTRY AND BIOPHYSICS REPORTS
(2023)
Article
Chemistry, Medicinal
Pritam Thapa et al.
Summary: This article discusses the association between the activation of NLRP3 inflammasome and disease conditions, as well as its potential as a target for treating chronic diseases. Sulfonylurea and Michael acceptor covalent inhibitors are among the known classes of NLRP3 inhibitors. Additionally, chalcone is studied as a promising scaffold for developing NLRP3 inhibitors. This review highlights chalcone derivatives with NLRP3 inhibitory activities.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY REPORTS
(2023)
